Innoviva (INVA) Net Cash Flow Growth (1y) (2011 - 2026)
Innoviva (INVA) Net Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,045.06 Bn | 1,045.06 Bn | - | - |
| 4 | BeOne Medicines | 470.64 Bn | 465.84 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 122.91 Bn | 115.67 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 70.07 Bn | 61.31 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.77 Bn | 62.77 Bn | - | - |
| 8 | Argenx Se | 56.21 Bn | 51.02 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.60 Bn | 37.60 Bn | - | - |
| 10 | Innoviva | 1.60 Bn | 997.33 Mn | 75.83 Mn | 269.13% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 269.13% |
| Sep 30, 2025 | 155.60% |
| Jun 30, 2025 | 102.98% |
| Mar 31, 2025 | 193.20% |
| Sep 30, 2024 | 160.44% |
| Jun 30, 2024 | 33.37% |
| Mar 31, 2024 | 89.69% |
| Sep 30, 2023 | -211.83% |
| Jun 30, 2023 | -56.61% |
| Mar 31, 2023 | -1,062.23% |
| Sep 30, 2022 | 189.16% |
| Jun 30, 2022 | 127.87% |
| Mar 31, 2022 | -58.03% |
| Sep 30, 2021 | -268.63% |
| Jun 30, 2021 | -491.76% |
| Mar 31, 2021 | -50.73% |
| Dec 31, 2020 | -321.31% |
| Sep 30, 2020 | 113.09% |
| Jun 30, 2020 | -20.36% |
| Mar 31, 2020 | 2,602.45% |